P. Morlat, Prise en Charge Médicale des Personnes Vivant Avec le VIH. Recommandations du Groupe D'experts. Rapport, p.476, 2013.

P. Morlat, C. Roussillon, and S. Henard, Causes of death among HIV-infected patients in France in 2010 (national survey): trends since, AIDS, vol.28, pp.1181-1191, 2000.

M. Frisch, R. J. Biggar, and E. A. Engels, Association of cancer with AIDS-related immunosuppression in adults, JAMA, vol.285, pp.1736-1745, 2001.

J. J. Goedert, T. R. Cote, and P. Virgo, Spectrum of AIDS-associated malignant disorders, Lancet, vol.351, pp.1833-1839, 1998.

A. Arvey, A. I. Ojesina, and C. S. Pedamallu, The tumor virus landscape of AIDSrelated lymphomas, Blood, vol.125, pp.14-22, 2015.

A. Chadburn, A. Chiu, and J. Y. Lee, Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034, J Clin Oncol, vol.27, pp.5039-5048, 2009.

C. Chao, M. J. Silverberg, and O. Martinez-maza, Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma, Clin Cancer Res, vol.18, pp.4702-4712, 2012.

A. E. Grulich, M. T. Van-leeuwen, M. O. Falster, and C. M. Vajdic, Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis, Lancet, vol.370, pp.59-67, 2007.

M. S. Shiels, S. R. Cole, G. D. Kirk, and C. Poole, A meta-analysis of the incidence of nonAIDS cancers in HIV-infected individuals, J Acquir Immune Defic Syndr, vol.52, pp.611-622, 2009.

J. P. Spano, D. Costagliola, and C. Katlama, AIDS-related malignancies: state of the art and therapeutic challenges, J Clin Oncol, vol.26, pp.4834-4842, 2008.

M. Bower, A. Palfreeman, and M. Alfa-wali, British HIV Association guidelines for HIV-associated malignancies 2014, HIV Med, vol.15, pp.1-92, 2014.

A. Ntekim, O. Campbell, and D. Rothenbacher, Optimal management of cervical cancer in HIV-positive patients: a systematic review, Cancer Med, vol.4, pp.1381-1393, 2015.

E. Arruda, A. A. Jacome, and A. L. Toscano, Consensus of the Brazilian Society of Infectious Diseases and Brazilian Society of Clinical Oncology on the management and treatment of Kaposi's sarcoma, Braz J Infect Dis, vol.18, pp.315-326, 2014.

M. Hentrich, C. Hoffmann, and F. Mosthaf, Therapy of HIV-associated lymphomarecommendations of the Oncology Working Group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNA), in cooperation with the German AIDS Society (DAIG), Ann Hematol, vol.93, pp.913-921, 2014.

H. A. Torres and V. Mulanovich, Management of HIV infection in patients with cancer receiving chemotherapy, Clin Infect Dis, vol.59, pp.106-114, 2014.

M. S. Shiels, R. M. Pfeiffer, and E. A. Engels, Age at cancer diagnosis among persons with AIDS in the United States, Ann Intern Med, vol.153, pp.452-460, 2010.

M. Hleyhel, Cancer Risk Group of the French Hospital Database on HIV. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort, AIDS, vol.28, pp.2109-2118, 2014.

K. P. Bhavan, V. N. Kampalath, and E. T. Overton, The aging of the HIV epidemic, Curr HIV/ AIDS Rep, vol.5, pp.150-158, 2008.

R. B. Effros, C. V. Fletcher, and K. Gebo, Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions, Clin Infect Dis, vol.47, pp.542-553, 2008.

E. C. Seaberg, D. Wiley, and O. Martinez-maza, Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to, Cancer, vol.116, pp.5507-5516, 2007.

C. Piketty, H. Selinger-leneman, and A. M. Bouvier, Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French Hospital Database on HIV, J Clin Oncol, vol.30, pp.4360-4366, 2012.

S. Franceschi, M. Lise, and G. M. Clifford, Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study, Br J Cancer, vol.103, pp.416-422, 2010.

M. Guiguet, F. Boue, and J. Cadranel, Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study, Lancet Oncol, vol.10, pp.1152-1159, 2009.

J. M. Palefsky and E. A. Holly, Chapter 6: immunosuppression and co-infection with HIV, J Natl Cancer Inst Monogr, pp.41-46, 2003.

M. J. Silverberg, C. Chao, and W. A. Leyden, HIV infection, immunodeficiency, viral replication, and the risk of cancer, Cancer Epidemiol Biomarkers Prev, vol.20, pp.2551-2559, 2011.

E. A. Engels, M. V. Brock, and J. Chen, Elevated incidence of lung cancer among HIV-infected individuals, J Clin Oncol, vol.24, pp.1383-1388, 2006.

A. K. Chaturvedi, R. M. Pfeiffer, and L. Chang, Elevated risk of lung cancer among people with AIDS, AIDS, vol.21, pp.207-213, 2007.

G. D. Kirk, C. Merlo, O. Driscoll, and P. , HIV infection is associated with an increased risk for lung cancer, independent of smoking, Clin Infect Dis, vol.45, pp.103-110, 2007.

M. Helleberg, J. Gerstoft, and S. Afzal, Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV, AIDS, vol.28, pp.1499-1508, 2014.

S. R. Pine, L. E. Mechanic, and L. Enewold, Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer, J Natl Cancer Inst, vol.103, pp.1112-1122, 2011.

R. Valiathan, M. J. Miguez, and B. Patel, Tobacco smoking increases immune activation and impairs T-cell function in HIV infected patients on antiretrovirals: a cross-sectional pilot study, PLoS One, vol.9, p.97698, 2014.

, Guideline on When to Start Antiretroviral Therapy and on pre-Exposure Prophylaxis for HIV, Data WLC-i-P Edition, 2015.

L. Tron, F. Lert, and B. Spire, Tobacco smoking in HIV-infected versus general population in France: heterogeneity across the various groups of people living with HIV, PLoS One, vol.9, p.107451, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01369609

F. T. Leone, S. Evers-casey, B. A. Toll, and A. Vachani, Treatment of tobacco use in lung cancer: diagnosis and management of lung cancer, Chest, vol.143, pp.61-77, 2013.

D. Mani, M. Haigentz, . Jr, and D. M. Aboulafia, Lung cancer in HIV infection, Clin Lung Cancer, vol.13, pp.6-13, 2012.

M. V. Brock, C. M. Hooker, and E. A. Engels, Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care, J Acquir Immune Defic Syndr, vol.43, pp.47-55, 2006.

D. 'jaen, G. A. Pantanowitz, L. Bower, and M. , Human immunodeficiency virusassociated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration, Clin Lung Cancer, vol.11, pp.396-404, 2010.

R. Rengan, N. Mitra, and K. Liao, Effect of HIV on survival in patients with nonsmall-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study, Lancet Oncol, vol.13, pp.1203-1209, 2012.

K. Sigel, J. Wisnivesky, and K. Gordon, HIV as an independent risk factor for incident lung cancer, AIDS, vol.26, pp.1017-1025, 2012.

G. Suneja, M. S. Shiels, and R. Angulo, Cancer treatment disparities in HIV-infected individuals in the United States, J Clin Oncol, vol.32, pp.2344-2350, 2014.

A. E. Coghill, M. S. Shiels, G. Suneja, and E. A. Engels, Elevated cancer-specific mortality among HIV-infected patients in the United States, J Clin Oncol, vol.33, pp.2376-2383, 2015.

M. Hleyhel, A. Belot, and A. M. Bouvier, Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort, Int J Cancer, vol.137, pp.2443-2453, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01166935

B. Besse, A. Adjei, and P. Baas, ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease, Ann Oncol, vol.25, pp.1475-1484, 2014.

J. Vansteenkiste, D. De-ruysscher, and W. E. Eberhardt, Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.24, issue.6, pp.89-98, 2013.

A. Makinson, J. C. Tenon, and S. Eymard-duvernay, Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study, J Thorac Oncol, vol.6, pp.1022-1029, 2011.

M. A. Rudek, C. Flexner, and R. F. Ambinder, Use of antineoplastic agents in patients with cancer who have HIV/AIDS, Lancet Oncol, vol.12, pp.905-912, 2011.

J. Deeken, J. Beumer, and A. N. , Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib, Cancer Chemother Pharmacol, vol.76, pp.813-819, 2015.

J. Brahmer, K. L. Reckamp, and P. Baas, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, vol.373, pp.123-135, 2015.

H. Borghaei, L. Paz-ares, and L. Horn, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, vol.373, pp.1627-1639, 2015.

A. M. Adams, Reduced lung-cancer mortality with low-dose computed tomographic screening, N Engl J Med, vol.365, pp.395-409, 2011.

A. Makinson, S. Eymard-duvernay, and F. Raffi, Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers. The ANRS EP48 HIV CHEST Study, AIDS, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01274227

A. Hulbert, C. M. Hooker, and J. C. Keruly, Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers, J Thorac Oncol, vol.9, pp.752-759, 2014.

N. Brau, R. K. Fox, and X. P. , Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study, J Hepatol, vol.47, pp.527-537, 2007.

C. Lim, N. Goutte, and A. Gervais, Standardized care management ensures similar survival rates in HIV-positive and HIV-negative patients with hepatocellular carcinoma, J Acquir Immune Defic Syndr, vol.61, pp.581-587, 2012.

J. Bruix and M. Sherman, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update, Hepatology, vol.53, pp.1020-1022, 2011.

, European Association For The Study of The L, European Organisation For R, Treatment of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, vol.56, pp.908-943, 2012.

C. Verslype, O. Rosmorduc, P. Rougier, and E. Group, Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis

, Ann Oncol, vol.23, issue.7, pp.41-48, 2012.

E. Wilkins, M. Nelson, and K. Agarwal, British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013, HIV Med, vol.14, issue.4, pp.1-71, 2013.

D. Benedetto, F. , D. Ruvo, N. Berretta, and M. , Hepatocellular carcinoma in HIV patients treated by liver transplantation, Eur J Surg Oncol, vol.34, pp.422-427, 2008.

D. Benedetto, F. , D. Sandro, S. , D. Ruvo et al., Human immunodeficiency virus and liver transplantation: our point of view, Transplant Proc, vol.40, pp.1965-1971, 2008.

D. Benedetto, F. Tarantino, G. Ercolani, and G. , Multicenter Italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients, Oncologist, vol.18, pp.592-599, 2013.

M. Berretta, E. Garlassi, and B. Cacopardo, Hepatocellular carcinoma in HIVinfected patients: check early, treat hard, Oncologist, vol.16, pp.1258-1269, 2011.

E. Vibert, J. C. Duclos-vallee, and M. R. Ghigna, Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection, Hepatology, vol.53, pp.475-482, 2011.

G. Nunnari, M. Berretta, and M. R. Pinzone, Hepatocellular carcinoma in HIV positive patients, Eur Rev Med Pharmacol Sci, vol.16, pp.1257-1270, 2012.

M. Gelu-simeon, R. Sobesky, and S. Haim-boukobza, Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIVinfected patients justify specific screening policies?, AIDS, vol.28, pp.1379-1391, 2014.

M. Berretta, D. Benedetto, F. , D. Maso, and L. , Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients, Anticancer Drugs, vol.24, pp.212-218, 2013.

V. Ozenne, A. Gervais, and G. Peytavin, Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report, Hepatogastroenterology, vol.58, pp.161-162, 2011.

L. Abramowitz, N. Mathieu, and F. Roudot-thoraval, Epidermoid anal cancer prognosis comparison among HIV+ and HIV-patients, Aliment Pharmacol Ther, vol.30, pp.414-421, 2009.

L. Abramowitz, A. C. Jacquard, and F. Jaroud, Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study, Int J Cancer, vol.129, pp.433-439, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00563122

R. Mendez-martinez, N. E. Rivera-martinez, and B. Crabtree-ramirez, Multiple human papillomavirus infections are highly prevalent in the anal canal of human immunodeficiency virus-positive men who have sex with men, BMC Infect Dis, vol.14, p.671, 2014.

A. Kreuter, A. Potthoff, and N. H. Brockmeyer, Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany, Br J Dermatol, vol.162, pp.1269-1277, 2010.

J. M. Palefsky, E. A. Holly, and J. T. Efirdc, Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men, AIDS, vol.19, pp.1407-1414, 2005.

A. J. Watson, B. B. Smith, and M. R. Whitehead, Malignant progression of anal intraepithelial neoplasia, ANZ J Surg, vol.76, pp.715-717, 2006.

S. Cleator, K. Fife, and M. Nelson, Treatment of HIV-associated invasive anal cancer with combined chemoradiation, Eur J Cancer, vol.36, pp.754-758, 2000.

R. F. Stadler, S. G. Gregorcyk, and D. M. Euhus, Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy, Dis Colon Rectum, vol.47, pp.1305-1309, 2004.

A. Wexler, A. M. Berson, and S. E. Goldstone, Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy, Dis Colon Rectum, vol.51, pp.73-81, 2008.

C. Oehler-janne, F. Huguet, and S. Provencher, HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy, J Clin Oncol, vol.26, pp.2550-2557, 2008.

Y. Seo, M. T. Kinsella, and H. L. Reynolds, Outcomes of chemoradiotherapy with 5Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients, Int J Radiat Oncol Biol Phys, vol.75, pp.143-149, 2009.

M. E. Hogg, D. A. Popowich, and E. C. Wang, HIV and anal cancer outcomes: a single institution's experience, Dis Colon Rectum, vol.52, pp.891-897, 2009.

L. Abramowitz, V. Remy, and A. Vainchtock, Economic burden of anal cancer management in France, Rev Epidemiol Sante Publique, vol.58, pp.331-338, 2010.

I. Fraunholz, C. Weiss, and K. Eberlein, Concurrent chemoradiotherapy with 5fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy, Int J Radiat Oncol Biol Phys, vol.76, pp.1425-1432, 2010.

N. Munoz-bongrand, T. Poghosyan, and S. Zohar, Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study, Dis Colon Rectum, vol.54, pp.729-735, 2011.

L. Quero, X. Duval, and L. Abramowitz,

, Bull Cancer, vol.101, pp.1034-1039, 2014.

G. Northover, J. M. Cervantes, A. Group, and E. , Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.21, issue.5, pp.87-92, 2010.

L. Cunin, M. Alfa-wali, and J. Turner, Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIVpositive individuals, Ann Surg Oncol, vol.21, pp.527-532, 2014.

C. Faivre, P. Rougier, and M. Ducreux, 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer, Bull Cancer, vol.86, pp.861-865, 1999.

I. A. Jaiyesimi and R. Pazdur, Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal, Am J Clin Oncol, vol.16, pp.536-540, 1993.

M. S. Shiels, E. H. Koritzinsky, and C. A. Clarke, Prevalence of HIV infection among U. S. Hodgkin lymphoma cases, Cancer Epidemiol Biomarkers Prev, vol.23, pp.274-281, 2014.

C. Besson, R. Lancar, and S. Prevot, High risk features contrast with favorable outcomes in HIV-associated Hodgkin lymphoma in the modern cART era, ANRS CO16 LYMPHOVIR Cohort, Clin Infect Dis, vol.61, pp.1469-1475, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01543677

M. Hentrich, M. Berger, and C. Wyen, Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study, J Clin Oncol, vol.30, pp.4117-4123, 2012.

S. Montoto, K. Shaw, and J. Okosun, HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era, J Clin Oncol, vol.30, pp.4111-4116, 2012.

T. S. Uldrick and R. F. Little, How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus, Blood, vol.125, pp.1226-1235, 2015.

B. Xicoy, J. M. Ribera, and P. Miralles, Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma, Haematologica, vol.92, pp.191-198, 2007.

J. J. Castillo, M. Bower, and J. Bruhlmann, Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study, Cancer, vol.121, pp.423-431, 2015.

J. Gabarre, A. G. Marcelin, and N. Azar, High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)related lymphoma: results and impact on HIV disease, Haematologica, vol.89, pp.1100-1108, 2004.

M. Gandhi and A. Petrich, Brentuximab vedotin in patients with relapsed HIV-related lymphoma, J Natl Compr Canc Netw, vol.12, pp.16-19, 2014.

, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services, 2015.

B. Hoen, F. Bonnet, and C. Delaugerre, guidelines for antiretroviral therapy of HIV-1 infection in adults, J Int AIDS Soc, vol.17, 2013.

, European Aids Clinical Society Guidelines In Edition Version 7.1. European AIDS Clinical Society, 2014.

J. L. Lennox, R. J. Landovitz, and H. J. Ribaudo, Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial, Ann Intern Med, vol.161, pp.461-471, 2014.

F. Raffi, A. G. Babiker, and L. Richert, Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial, Lancet, vol.384, pp.1942-1951, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01108186

B. Clotet, J. Feinberg, and J. Van-lunzen, Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study, Lancet, vol.383, pp.2222-2231, 2014.

J. F. Deeken, L. Pantanowitz, and B. J. Dezube, Targeted therapies to treat non-AIDSdefining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook, Curr Opin Oncol, vol.21, pp.445-454, 2009.

K. C. Brown, S. Paul, and A. D. Kashuba, Drug interactions with new and investigational antiretrovirals, Clin Pharmacokinet, vol.48, pp.211-241, 2009.

L. Dickinson, S. Khoo, and D. Back, Pharmacokinetics and drug-drug interactions of antiretrovirals: an update, Antiviral Res, vol.85, pp.176-189, 2010.

M. Cianfrocca, S. Lee, V. Roenn, and J. , Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial, Cancer Chemother Pharmacol, vol.68, pp.827-833, 2011.

G. Corona, E. Vaccher, and S. Sandron, Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma, Clin Pharmacol Ther, vol.83, pp.601-606, 2008.

M. A. Rudek, P. C. Moore, and R. T. Mitsuyasu, A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061, Cancer, vol.120, pp.1194-1202, 2014.

J. L. Perez-gracia, S. Labiano, . Rodriguez-ruiz, and . Me, Orchestrating immune check-point blockade for cancer immunotherapy in combinations, Curr Opin Immunol, vol.27, pp.89-97, 2014.
DOI : 10.1016/j.coi.2014.01.002

J. R. Westin, F. Chu, and M. Zhang, Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, Lancet Oncol, vol.15, pp.69-77, 2014.

J. M. Taube, A. Klein, and J. R. Brahmer, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD1 therapy, Clin Cancer Res, vol.20, pp.5064-5074, 2014.

C. L. Day, D. E. Kaufmann, and P. Kiepiela, PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression, Nature, vol.443, pp.350-354, 2006.
DOI : 10.1038/nature05115

L. Trautmann, L. Janbazian, and N. Chomont, Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction, Nat Med, vol.12, pp.1198-1202, 2006.